Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
MannKind Corporation (MNKD): Analyst Targets Point to +104% Upside Potential

MannKind Corporation (MNKD): Analyst Targets Point to +104% Upside Potential

Key Takeaways

  • The central target of $8.30 is the arithmetic mean of nine verified analyst price targets, rounded from an unrounded average of $8.33.
  • With MannKind Corporation (MNKD) recently trading near $4.07, reaching $8.30 would require a gain of roughly 104% — a very large move.
  • The nine targets span a wide range from $5.00 to $13.00, with eight buy/overweight ratings and one hold, reflecting a "Strong Buy" leaning but little agreement on magnitude.
  • Key supports include durable Tyvaso DPI royalty income, the pediatric Afrezza launch, and the Furoscix/ReadyFlow ramp.
  • The biggest risks are a third-quarter revenue miss, recurring GAAP losses, and the earlier discontinuation of the MNKD-101 clinical program.
  • Explore Major News, Today's Price Move, the Forecast, and Earnings pages for deeper coverage of MNKD's developments and outlook.
  • For automated trading ideas, explore Trending AI Robots.

Understanding the Analyst Price Targets

The $8.30 figure is not an official published consensus; it is an average calculated from nine individual analyst price targets that are attributable to named firms. The range runs from $5.00 at the low end to $13.00 at the high end, and the unrounded mean is approximately $8.33. That wide dispersion is itself informative: analysts agree the shares are undervalued on a directional basis, but disagree sharply on how much upside is justified.

At the cautious end, RBC Capital carries a Hold with a $5 target, and Truist Financial (Gregory Renza) maintained a Buy but trimmed its target to $5 in early October 2026. In the middle, Mizuho and Raymond James both hold $7 targets, while Wedbush's Yun Zhong reiterated a Buy with an $8 target. Cantor Fitzgerald raised its target to $10 from $8, H.C. Wainwright reiterated at $10, and Chardan Capital initiated coverage with a $10 target in October 2026. Wells Fargo remains the most bullish at $13, an Overweight rating it has kept even after prior reductions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Bullish arguments center on Tyvaso DPI royalty durability and new product launches, while cautious views reflect the company's third-quarter revenue shortfall and the loss of pipeline optionality after the Phase 3 ICoN-1 trial for MNKD-101 was discontinued following a futility assessment. The average should be read as a statistical midpoint across differing opinions, not a guarantee.

Current Market Position

MannKind Corporation (MNKD) shares have traded in a volatile range in late 2026, recently around $4.07 after slipping from levels near $4.13 earlier in November. The stock is well below its 52-week high near $6.51 and above its 52-week low near $2.23. At approximately $4.07, the $8.30 target implies upside of about 104%, which is a very large required move by any standard measure.

Fundamentals are improving unevenly. Third-quarter 2026 revenue rose roughly 24% year over year to about $101.9 million, yet that figure came in below consensus estimates near $107.7 million. The company posted an EPS of about -$0.01, better than the roughly -$0.06 to -$0.07 analysts had expected, but MannKind continues to report GAAP losses. Management has highlighted a settlement with Liquidia and United Therapeutics as supportive of near-term Tyvaso DPI royalty durability, and pointed to accelerating pediatric Afrezza adoption as well as the early launch of ReadyFlow, the furosemide delivery device, alongside the Furoscix franchise. A path toward $8.30 would likely require sustained revenue growth, expanding profitability, and successful execution across these launches — a multi-quarter journey, not a single-catalyst event.

Potential Catalysts Supporting the Target

  • Tyvaso DPI royalties: The company manufactures Tyvaso DPI for United Therapeutics and has signaled roughly $1 billion in combined royalties, milestones, and manufacturing revenue through 2030.
  • Pediatric Afrezza: The pediatric indication is ramping faster than the adult business, with management citing strong prescriber adoption and growing awareness.
  • Furoscix and ReadyFlow: The newer furosemide franchise offers a fresh revenue stream in heart-failure treatment.
  • Revenue growth: Consensus estimates point to roughly 26% revenue growth in fiscal 2026 and continued expansion into 2027.
  • Positive analyst bias: The eight-to-one buy-versus-hold split reflects a broadly constructive, though not uniform, Street view.

Risks That Could Hinder Progress

  • Revenue shortfalls: The Q3 revenue miss shows demand assumptions can overshoot realized sales.
  • Persistent losses: GAAP losses and a low or negative trailing EPS limit fundamental valuation support in the near term.
  • Pipeline setback: The discontinuation of MNKD-101 reduced future optionality and prompted several target cuts.
  • Launch execution: ReadyFlow and pediatric Afrezza must convert early interest into durable, paying demand.
  • Volatility and competition: The shares have fallen more than 30% over the trailing 12 months, and inhaled-therapy and diabetes markets remain competitive.

Technical Levels to Watch

The shares are trading in the lower half of a 52-week range of roughly $2.23 to $6.51. Near-term support sits in the $3.85–$4.00 zone, where the stock has repeatedly found buying interest, while the $5.00–$5.50 area has acted as resistance on prior advances. The psychological $5 level, which also coincides with the lowest analyst target, is a meaningful first hurdle. Beyond that, the $6.50 prior high represents a longer-term ceiling that would likely need to be cleared before the $8.30 objective becomes realistic.

Monitoring Key Metrics Going Forward

Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts set different assumptions. Investors should watch quarterly revenue versus estimates, EPS progression, pediatric Afrezza prescription trends, ReadyFlow and Furoscix launch metrics, Tyvaso DPI royalty updates, and any new pipeline or business-development announcements. Analyst target revisions — which have moved both up and down in 2026 — will also signal shifting conviction.

Using AI Daily Buy/Sell Signals in My Process

Tickeron's AI Daily Buy/Sell Signals help me monitor market conditions and technical behavior across thousands of stocks without constant manual checks. For a name like MannKind Corporation (MNKD) with upcoming commercial catalysts, these signals provide an efficient way to track shifts in momentum alongside my fundamental analysis. I find this approach useful for staying disciplined when volatility is high.

Final Assessment

The $8.30 central target, derived as the average of nine analyst price targets spanning $5.00 to $13.00, sits roughly 104% above the recent price near $4.07. Reaching it would require a very large repricing driven by sustained revenue growth, expanding profitability, and successful commercial execution across Tyvaso DPI royalties, pediatric Afrezza, and the Furoscix/ReadyFlow franchise. The main obstacles are the recent revenue miss, persistent GAAP losses, and the loss of MNKD-101 pipeline optionality. The unusually wide analyst range underscores genuine disagreement about how much of that potential is real. The target is an analytical reference point, not a forecast or a recommendation, and investors should weigh the supporting catalysts against the execution risks before forming their own view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MNKD

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for MNKD turns negative, indicating new downward trend

MNKD saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 74 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for MNKD moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 58 cases where MNKD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.

The Moving Average Convergence Divergence Histogram (MACD) for MNKD turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

MNKD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

MNKD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MNKD crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNKD advanced for three days, in 203 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 143 of 190 cases where MNKD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.662) is normal, around the industry mean (3.596). P/E Ratio (-26.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.832) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MNKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products

Industry Biotechnology

Industry
Biotechnology
Address
1 Casper Street
Phone
+1 818 661-5000
Employees
592
Web
https://www.mannkindcorp.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.